merged_alzheimers-treatment-kisunla-donanemab.txt
<other>I will now answer the questions based only on the provided article. I will go through each question one by one and extract the answer from the text.</other>
<question_number>1</question_number>
<answer>The belief that the significant safety risks, including swelling and bleeding in the brain, outweighed the potential for a slight benefit.</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for other, potentially better treatments, thereby slowing progress.</answer>
<question_number>3</question_number>
<answer>There is no correlation between the removal of amyloid plaques and the clinical response in individual subjects.</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>The higher price reflects the expectation that patients can stop taking the drug after their amyloid plaques are cleared, which could reduce the overall cost of treatment.</answer>
<question_number>6</question_number>
<answer>The emphasis on anti-amyloid drugs might discourage patients from participating in trials for treatments that could be better.</answer>
<question_number>7</question_number>
<answer>By allowing patients to stop the drug after amyloid is cleared and by being administered monthly instead of every two weeks.</answer>
<question_number>8</question_number>
<answer>Amyloid.</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius.</answer>
<question_number>10</question_number>
<answer>The finding that trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels.</answer>